HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan
ConditionSolid Tumor Malignancy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorPharmaEssentia
About this trial
This is a prospective observational research to explore the frequency of Human leukocyte antigen A allele 02:01 (HLA\*02:01) and the expression status of New York esophageal squamous cell carcinoma-1 (NY-ESO-1) in cancer patients in Taiwanese population.
Eligibility criteria
Qualifiers
Able to understand and voluntarily sign an informed consent form (ICF).
Adult aged ≥ 18 years at the time of informed consent (or other age required by local regulations).
Head and neck squamous cell carcinoma, excluding nasopharyngeal carcinoma;
Hepatocellular carcinoma;
Disqualifiers
Known primary immunodeficiency (such as Severe Combined Immunodeficiency Disease or AIDS).
Uncontrolled intercurrent illness which is not suitable for enrollment at the discretion of the investigator, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements.
Currently confirmed diagnosis of at least 2 active cancers; patient who was cured of the other cancer [disease free period > 6 months] and currently has only one research targeted tumor can be enrolled.
Untreated or symptomatic brain metastasis.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov